Statin exposure and thrombosis risk in patients with myeloproliferative neoplasms.
Aurélien Delluc, Karine Lacut, Brigitte Pan-Petesch...
https://pubmed.ncbi.nlm.nih.gov/29787944Actively Recruiting
Led by University Hospital, Brest · Updated on 2024-08-12
1000
Participants Needed
1
Research Sites
N/A
Total Duration
This observational study includes patients diagnosed or followed at Brest University Hospital with Philadelphia negative myeloproliferative neoplasms, specifically polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The study aims to collect and analyze clinical and biological data from diagnosis through ongoing follow-up to better understand disease progression and outcomes. Clinical information gathered includes patient and disease characteristics at diagnosis, mutational status, cardiovascular risk factors, and history of thrombosis or cancer. Biological data such as hemogram and bone marrow results are recorded when available. During follow-up, treatment changes and their reasons, thrombotic events, phenotypic changes, and deaths with their causes are noted. Participants are observed until the last update, such as death or change of care center. The main outcome measured is overall survival over 10 years, with secondary outcomes including incidence of disease evolutions and thromboses over the same period. Patients who are alive are asked to sign a consent form to continue in the study.
CONDITIONS
Myeloproliferative Neoplastic Diseases Observatory From Brest
You may qualify if you...
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants who undergo routine care are observed over time with clinical and biological data collected from diagnosis until last news.
Visits as per routine healthcare and follow-up
Total: 1 location
1
CHRU de Brest
Brest, France, 29609
Actively Recruiting
J
Jean-Christophe Ianotto
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Aurélien Delluc, Karine Lacut, Brigitte Pan-Petesch...
https://pubmed.ncbi.nlm.nih.gov/29787944Lise-Marie Mollard, Aurélie Chauveau, Françoise Boyer-Perrard...
https://pubmed.ncbi.nlm.nih.gov/29616837Olivier Mansier, Damien Luque Paz, Jean-Christophe Ianotto...
https://pubmed.ncbi.nlm.nih.gov/29266414Ronan Le Calloch, Karine Lacut, Christelle Le Gall-Ianotto...
https://pubmed.ncbi.nlm.nih.gov/29246923Jean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard...
https://pubmed.ncbi.nlm.nih.gov/29217781Kristell Mahé, Aurélien Delluc, Aurélie Chauveau...
https://pubmed.ncbi.nlm.nih.gov/29164292Jean-Christophe Ianotto, Marie-Anne Couturier, Hubert Galinat...
https://pubmed.ncbi.nlm.nih.gov/28623609Lenaïg Le Clech, Mehdi Sakka, Ahmed Meskar...
https://pubmed.ncbi.nlm.nih.gov/28482711C Le Gall-Ianotto, E Brenaut, M Gouillou...
https://pubmed.ncbi.nlm.nih.gov/27291777Christelle Le Gall-Ianotto, Lanig Civi, Brigitte Pan-Petesch...
https://pubmed.ncbi.nlm.nih.gov/41393215